Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James C Coons

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Respiratory Medicine|July 10, 2024
Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensusJacqueline Brewer, Melisa Wilson, James C Coons, et al.
Pulmonary Circulation|May 4, 2022
An expert panel Delphi consensus statement on the use of palliative care in the management of patients with pulmonary arterial hypertensionMelisa Wilson, Rebekah H Anguiano, Rana L A Awdish, et al.
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality|April 17, 2025
A Platform Designed to Empower Quality Improvement for Patients with Atrial FibrillationThomas F Deering, Anne Marie Smith, John A Gillespie, et al.
The European Respiratory Journal|August 7, 2025
Pericardial Effusions And Sotatercept Therapy in Pulmonary Arterial Hypertension: A Multicenter Real-World ExperienceSandeep Sahay, Nelson Villasmil Hernandez, Yassmin Al Aaraj, et al.
Clinical Pharmacology and Therapeutics|October 28, 2022
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y<sub>12</sub> Inhibitor Prescribing After Percutaneous Coronary InterventionLarisa H Cavallari, Nita A Limdi, Amber L Beitelshees, et al.
Clinical Pharmacology and Therapeutics|September 8, 2020
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary InterventionCraig R Lee, Cameron D Thomas, Amber L Beitelshees, et al.
Journal of the American Heart Association|February 14, 2022
<i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical SettingsAmber L Beitelshees, Cameron D Thomas, Philip E Empey, et al.
Clinical Pharmacology and Therapeutics|December 28, 2017
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet TherapyPhilip E Empey, James M Stevenson, Sony Tuteja, et al.
JACC. Cardiovascular Interventions|November 6, 2017
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary InterventionLarisa H Cavallari, Craig R Lee, Amber L Beitelshees, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Respiratory Medicine|July 10, 2024
Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensusJacqueline Brewer, Melisa Wilson, James C Coons, et al.
Pulmonary Circulation|May 4, 2022
An expert panel Delphi consensus statement on the use of palliative care in the management of patients with pulmonary arterial hypertensionMelisa Wilson, Rebekah H Anguiano, Rana L A Awdish, et al.
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality|April 17, 2025
A Platform Designed to Empower Quality Improvement for Patients with Atrial FibrillationThomas F Deering, Anne Marie Smith, John A Gillespie, et al.
The European Respiratory Journal|August 7, 2025
Pericardial Effusions And Sotatercept Therapy in Pulmonary Arterial Hypertension: A Multicenter Real-World ExperienceSandeep Sahay, Nelson Villasmil Hernandez, Yassmin Al Aaraj, et al.
Clinical Pharmacology and Therapeutics|October 28, 2022
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y<sub>12</sub> Inhibitor Prescribing After Percutaneous Coronary InterventionLarisa H Cavallari, Nita A Limdi, Amber L Beitelshees, et al.
Clinical Pharmacology and Therapeutics|September 8, 2020
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary InterventionCraig R Lee, Cameron D Thomas, Amber L Beitelshees, et al.
Journal of the American Heart Association|February 14, 2022
<i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical SettingsAmber L Beitelshees, Cameron D Thomas, Philip E Empey, et al.
Clinical Pharmacology and Therapeutics|December 28, 2017
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet TherapyPhilip E Empey, James M Stevenson, Sony Tuteja, et al.
JACC. Cardiovascular Interventions|November 6, 2017
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary InterventionLarisa H Cavallari, Craig R Lee, Amber L Beitelshees, et al.
Pageof 8